A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences.
Rapport bags $150M Series B just five months after nine-figure launch for epilepsy, psychiatry trials
Just five months after emerging with $100 million to test former Janssen neuroscience programs, Rapport Therapeutics is back with another nine-figure raise to take its
August 24, 2023